SG11202002267UA - Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase - Google Patents
Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferaseInfo
- Publication number
- SG11202002267UA SG11202002267UA SG11202002267UA SG11202002267UA SG11202002267UA SG 11202002267U A SG11202002267U A SG 11202002267UA SG 11202002267U A SG11202002267U A SG 11202002267UA SG 11202002267U A SG11202002267U A SG 11202002267UA SG 11202002267U A SG11202002267U A SG 11202002267UA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- compounds useful
- carboxyl methyltransferase
- isoprenylcysteine carboxyl
- isoprenylcysteine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201707444W | 2017-09-12 | ||
PCT/SG2018/050466 WO2019054944A1 (en) | 2017-09-12 | 2018-09-12 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002267UA true SG11202002267UA (en) | 2020-04-29 |
Family
ID=65722547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002267UA SG11202002267UA (en) | 2017-09-12 | 2018-09-12 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase |
Country Status (8)
Country | Link |
---|---|
US (1) | US11834430B2 (en) |
EP (1) | EP3681878A4 (en) |
JP (1) | JP7334979B2 (en) |
KR (1) | KR20200090747A (en) |
CN (1) | CN111344284B (en) |
AU (1) | AU2018332634A1 (en) |
SG (1) | SG11202002267UA (en) |
WO (1) | WO2019054944A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205465A1 (en) * | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2248491A (en) * | 1941-07-08 | Chs-chs | ||
US2196576A (en) * | 1938-12-16 | 1940-04-09 | Dow Chemical Co | Glycol ether |
DE3331692A1 (en) * | 1983-09-02 | 1985-03-28 | Basf Ag, 6700 Ludwigshafen | 3-PHENYL-4-METHOXYCARBONYLPYRAZOLE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
US6204293B1 (en) * | 1995-11-06 | 2001-03-20 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
CN1228338C (en) * | 2000-06-28 | 2005-11-23 | 久光医药股份有限公司 | Imidazole derivatives or salts thereof and drugs contg. derivatives or salts |
WO2002006237A1 (en) * | 2000-07-18 | 2002-01-24 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine comprising dicyanopyridine derivative |
MY140724A (en) * | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
EP1506040A2 (en) | 2002-05-16 | 2005-02-16 | Pharmacia Corporation | Selective inos inhibitors for the treatment of respiratory diseases and conditions |
JP2004262890A (en) * | 2003-03-04 | 2004-09-24 | Taisho Pharmaceut Co Ltd | Azole derivative having 20-hete production inhibiting action |
WO2005063732A1 (en) * | 2003-12-23 | 2005-07-14 | Microbia, Inc. | Compounds and methods for the treatment of asthma |
JP2005298406A (en) * | 2004-04-12 | 2005-10-27 | Fuji Photo Film Co Ltd | 5-aminopyrazole compound, and recording material containing the compound |
CN1944383A (en) * | 2005-01-11 | 2007-04-11 | 中国医学科学院药物研究所 | Alpha-alkoxy propionic acid compounds and their preparing method and medicine use |
JPWO2006109846A1 (en) * | 2005-04-06 | 2008-11-20 | 武田薬品工業株式会社 | Triazole derivatives and uses thereof |
JP2009545597A (en) | 2006-08-01 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | Sphingosine-1-phosphate receptor (SLP) agonist |
US7977371B2 (en) | 2007-02-26 | 2011-07-12 | Santen Pharmaceutical Co., Ltd. | Pyrrole derivative having ureido group and aminocarbonyl group as substituents |
WO2008126899A1 (en) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 5-membered heterocyclic derivative and use thereof for medical purposes |
KR20090077091A (en) | 2008-01-10 | 2009-07-15 | 일동제약주식회사 | New peroxisom proliferator-activated receptor compounds and preparing method thereof |
EP2350030B9 (en) | 2008-11-19 | 2016-10-26 | Council Of Scientific & Industrial Research | Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof |
WO2011014128A1 (en) * | 2009-07-30 | 2011-02-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
EP2670739B1 (en) | 2011-02-04 | 2015-04-01 | Council Of Scientific & Industrial Research | Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof |
WO2014041349A1 (en) * | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
SG11201600108PA (en) | 2013-07-17 | 2016-02-26 | Otsuka Pharma Co Ltd | Cyanotriazole compounds |
WO2016044556A2 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
JP6817962B2 (en) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | Compounds and methods for targeted androgen receptor degradation |
WO2017136699A1 (en) * | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
-
2018
- 2018-09-12 AU AU2018332634A patent/AU2018332634A1/en not_active Abandoned
- 2018-09-12 US US16/646,693 patent/US11834430B2/en active Active
- 2018-09-12 EP EP18856093.2A patent/EP3681878A4/en active Pending
- 2018-09-12 CN CN201880072698.4A patent/CN111344284B/en active Active
- 2018-09-12 SG SG11202002267UA patent/SG11202002267UA/en unknown
- 2018-09-12 WO PCT/SG2018/050466 patent/WO2019054944A1/en unknown
- 2018-09-12 JP JP2020515184A patent/JP7334979B2/en active Active
- 2018-09-12 KR KR1020207010540A patent/KR20200090747A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20200090747A (en) | 2020-07-29 |
JP7334979B2 (en) | 2023-08-29 |
EP3681878A1 (en) | 2020-07-22 |
WO2019054944A1 (en) | 2019-03-21 |
CN111344284A (en) | 2020-06-26 |
US20210130317A1 (en) | 2021-05-06 |
EP3681878A4 (en) | 2021-02-24 |
AU2018332634A1 (en) | 2020-04-30 |
JP2020533386A (en) | 2020-11-19 |
CN111344284B (en) | 2024-03-12 |
US11834430B2 (en) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3541932A4 (en) | Inhibitors of crispr-cas9 | |
HK1220409A1 (en) | Novel compounds and compositions for inhibition of fasn fasn | |
EP3188730A4 (en) | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
PT3371152T (en) | Compositions comprising an inhibitor of lysine specific demethylase-1 | |
IL261170B (en) | Carboxamide derivatives useful as rsk inhibitors | |
EP3188732A4 (en) | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
EP3188731A4 (en) | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
EP4063358C0 (en) | Histone methyltransferase inhibitors | |
EP3405477C0 (en) | Inhibitors of transglutaminases | |
IL254430A0 (en) | Heterocyclic compounds useful as inhibitors of tnf | |
GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
HK1231484A1 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 tnks1 / tnks2 | |
PT3458448T (en) | Methods of using fasn inhibitors | |
GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
HK1257565A1 (en) | New trifluoromethylpropanamide derivatives as htra1 inhibitors | |
HK1257567A1 (en) | New difluoroketamide derivatives as htra1 inhibitors | |
HK1253572A1 (en) | Pyrido-oxazinone derivatives as tnap inhibitors | |
HK1252767A1 (en) | Pyrazol-pyridine derivatives as eaat3 inhibitors | |
IL271066A (en) | Azaindole compounds as histone methyltransferase inhibitors | |
SG11202002267UA (en) | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | |
GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
AU2016205137B2 (en) | Furoquinolinediones as inhibitors of TDP2 | |
IL277869A (en) | Substituted propanamides as inhibitors of nucleases | |
IL266121A (en) | Substituted quinoxaline derivatives as inhibitors of pfkfb |